Ku­ra shares soar on pos­i­tive PhII can­cer da­ta; M&A buzz re­volves back to As­traZeneca

⇨ In­vestors are in an en­thu­si­as­tic mood when it comes to any­thing that looks pos­i­tive on the can­cer drug de­vel­op­ment side of things. To­day Ku­ra On­col­o­gy ben­e­fit­ed from that ex­u­ber­ance, with its stock price up 70% this morn­ing af­ter the biotech re­port­ed that its can­cer drug tip­i­farnib hit the pri­ma­ry end­point in a Phase II tri­al. The tri­al pro­to­col re­quires four con­firmed, par­tial re­spons­es, per RE­CIST 1.1 cri­te­ria, out of 18 pa­tients to meet its pri­ma­ry end­point. “We have ob­served rapid and, in some cas­es, dra­mat­ic re­spons­es in pa­tients with re­lapsed and/or re­frac­to­ry HN­SCC who do not ap­pear to ben­e­fit from oth­er ther­a­pies,” said An­to­nio Gual­ber­to, the CMO at Ku­ra.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER